An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction.
Irfan CicinMohammed OukkalHassen MahfoufAmel MezlınıBlaha LarbaouiSlim Ben AhmedHassan ErrihaniKhalid AlsalehRhizlane BelbarakaPerran Fulden YumukBurçe GöktaşMustafa ÖzgüroğluPublished in: European journal of breast health (2021)
SC trastuzumab was widely acceptable to both patients and HCPs. The safety and tolerability of SC trastuzumab was consistent with the known safety profile of SC and IV administration.